JFA
VIRX

JNBA Financial Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

JNBA Financial Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2
Closed – – 1403
2016
Q3 		$0 Buy
+2
New +$282 ﹤0.01% 1682

Other funds holding VIRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

JNBA Financial Advisors's VIRX Position: Q4 2016 in Review

JNBA Financial Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2016, closing a stake of 2 shares.

JNBA Financial Advisors first reported a position in VIRX in Q3 2016 and held it in 1 quarter. The position peaked at $0 in Q3 2016. 45 funds tracked by Wall St. Rank hold VIRX as of Q4 2016.

  • JNBA Financial Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • JNBA Financial Advisors sold 2 Viracta Therapeutics, Inc. Common Stock shares in Q4 2016.
  • JNBA Financial Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2016 and held it in 1 quarter.
  • JNBA Financial Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $0 in Q3 2016.
  • 45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2016.

Based on JNBA Financial Advisors's 13F filing for Q4 2016, filed 3 Feb 2017.